These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 29652548

  • 1. CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.
    Nicolaides NC, Schweizer C, Somers EB, Wang W, Fernando S, Ross EN, Grasso L, Hassan R, Kline JB.
    Cancer Biol Ther; 2018 Jul 03; 19(7):622-630. PubMed ID: 29652548
    [Abstract] [Full Text] [Related]

  • 2. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.
    Clin Cancer Res; 2014 Dec 01; 20(23):5927-36. PubMed ID: 25231400
    [Abstract] [Full Text] [Related]

  • 3. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.
    Cancer; 2014 Nov 01; 120(21):3311-9. PubMed ID: 24989332
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection.
    Gupta A, Hussein Z, Hassan R, Wustner J, Maltzman JD, Wallin BA.
    Cancer Chemother Pharmacol; 2016 Apr 01; 77(4):733-43. PubMed ID: 26898299
    [Abstract] [Full Text] [Related]

  • 5. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly K.
    J Clin Oncol; 2019 Oct 01; 37(28):2537-2547. PubMed ID: 31386610
    [Abstract] [Full Text] [Related]

  • 6. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A, French Cooperative Thoracic Intergroup (IFCT).
    Lancet; 2016 Apr 02; 387(10026):1405-1414. PubMed ID: 26719230
    [Abstract] [Full Text] [Related]

  • 7. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK, Lesterhuis WJ, Kok PS, Brown C, Hughes BG, Karikios DJ, John T, Kao SC, Leslie C, Cook AM, Pavlakis N, Briscoe K, O'Byrne KJ, Karapetis CS, Lam WS, Langford A, Yip S, Stockler MR.
    Lancet Oncol; 2020 Sep 02; 21(9):1213-1223. PubMed ID: 32888453
    [Abstract] [Full Text] [Related]

  • 8. Antitumor effect of novel anti-podoplanin antibody NZ-12 against malignant pleural mesothelioma in an orthotopic xenograft model.
    Abe S, Kaneko MK, Tsuchihashi Y, Izumi T, Ogasawara S, Okada N, Sato C, Tobiume M, Otsuka K, Miyamoto L, Tsuchiya K, Kawazoe K, Kato Y, Nishioka Y.
    Cancer Sci; 2016 Sep 02; 107(9):1198-205. PubMed ID: 27294401
    [Abstract] [Full Text] [Related]

  • 9. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
    Buikhuisen WA, Burgers JA, Vincent AD, Korse CM, van Klaveren RJ, Schramel FM, Pavlakis N, Nowak AK, Custers FL, Schouwink JH, Gans SJ, Groen HJ, Strankinga WF, Baas P.
    Lancet Oncol; 2013 May 02; 14(6):543-51. PubMed ID: 23583604
    [Abstract] [Full Text] [Related]

  • 10. Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly K.
    J Thorac Oncol; 2017 Aug 02; 12(8):1299-1308. PubMed ID: 28599887
    [Abstract] [Full Text] [Related]

  • 11. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.
    Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG.
    Clin Cancer Res; 2019 Oct 01; 25(19):5787-5798. PubMed ID: 31263030
    [Abstract] [Full Text] [Related]

  • 12. Use of Serum Mesothelin as an Indicator of Tumor Progression in Routine Clinical Practice of Malignant Pleural Mesothelioma Treatment.
    Vigani A, Pistillo MP, Fontana V, Giannoni U, Rosenberg I, Canessa PA, Berisso G, Ferro P, Franceschini MC, Tonarelli M, Roncella S.
    J Thorac Oncol; 2018 Aug 01; 13(8):e143-e145. PubMed ID: 30049376
    [No Abstract] [Full Text] [Related]

  • 13. Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma.
    Mansfield AS, Vivien Yin J, Bradbury P, Kwiatkowski DJ, Patel S, Bazhenova LA, Forde P, Lou Y, Dizona P, Villaruz LC, Arnold SM, Khalil M, Kindler HL, Koczywas M, Pacheco J, Rolfo C, Xia B, Mikula E, Chen L, Patel K, Smith KER, Cao L, Shapiro G, Costello BA, Adjei A, Sharon E, Moscow JA, Zamboni W, Hassan R.
    Lung Cancer; 2024 Sep 01; 195():107928. PubMed ID: 39197359
    [Abstract] [Full Text] [Related]

  • 14. A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol.
    Fujimoto N, Aoe K, Kozuki T, Oze I, Kato K, Kishimoto T, Hotta K.
    Clin Lung Cancer; 2018 Sep 01; 19(5):e705-e707. PubMed ID: 29853412
    [Abstract] [Full Text] [Related]

  • 15. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL, Aerts JG, Dziadziuszko R, Ramlau R, Cedres S, van Meerbeeck JP, Mencoboni M, Planchard D, Chella A, Crinò L, Krzakowski M, Rüssel J, Maconi A, Gianoncelli L, Grosso F.
    Lancet Oncol; 2019 Dec 01; 20(12):1702-1709. PubMed ID: 31628016
    [Abstract] [Full Text] [Related]

  • 16. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.
    Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA, McCoy MJ, Robinson BW, Lake RA.
    Ann Oncol; 2015 Dec 01; 26(12):2483-90. PubMed ID: 26386124
    [Abstract] [Full Text] [Related]

  • 17. First-line chemotherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma.
    Fujimoto E, Kijima T, Kuribayashi K, Negi Y, Kanemura S, Mikami K, Doi H, Kitajima K, Nakano T.
    Expert Rev Anticancer Ther; 2017 Sep 01; 17(9):865-872. PubMed ID: 28594258
    [Abstract] [Full Text] [Related]

  • 18. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
    Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PLR, Pavlakis N, Boyer M, Stockler MR.
    Lung Cancer; 2013 Sep 01; 81(3):422-427. PubMed ID: 23787063
    [Abstract] [Full Text] [Related]

  • 19. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
    Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, Sharma S.
    Lung Cancer; 2014 Sep 01; 85(3):429-34. PubMed ID: 25047675
    [Abstract] [Full Text] [Related]

  • 20. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
    Miyamoto Y, Kozuki T, Aoe K, Wada S, Harada D, Yoshida M, Sakurai J, Hotta K, Fujimoto N.
    J Immunother Cancer; 2021 Oct 01; 9(10):. PubMed ID: 34711664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.